Krystal Biotech Inc

Krystal Biotech, Inc. (NASDAQ: KRYS) is a fully integrated, commercial-stage, global biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company's first commercial product, VYJUVEK (beremagene geperpavec-svdt), is a non-invasive, topical, redosable gene therapy approved in the United States, Europe, and Japan for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB). VYJUVEK delivers functional copies of the COL7A1 gene directly to wounds, enabling production of normal COL7 protein. Beyond DEB, Krystal is advancing a diversified pipeline spanning ophthalmology (KB803 for DEB corneal abrasions, KB801 for neurotrophic keratitis), respiratory (KB407 for cystic fibrosis, KB408 for alpha-1 antitrypsin deficiency), dermatology (KB111 for Hailey-Hailey disease), and oncology (inhaled and intratumoral KB707 for non-small cell lung cancer and Gorlin syndrome). Through its wholly owned subsidiary Jeune Aesthetics, Inc., the company is also developing KB304 for aesthetics applications. Krystal's platform leverages herpes simplex virus type 1 (HSV-1) vectors for gene delivery across multiple therapeutic areas. Updated Aug 3, 2026